Crinetics Pharma (CRNX)
NASDAQ:CRNX
Want to see CRNX full AI Analyst Report?
CRNX Stock Chart & Stats
$41.00
-$0.61(-1.22%)
At close: 4:00 PM EST
$41.00
-$0.61(-1.22%)
Day’s Range― - ―
52-Week Range$25.83 - $57.99
Previous CloseN/A
Volume214.21K
Average Volume (3M)1.27M
Market Cap
$3.44B
Enterprise Value$3.68B
Total Cash (Recent Filing)$1.29B
Total Debt (Recent Filing)$47.85M
Price to Earnings (P/E)―
Beta1.44
Next Earnings
Aug 11, 2026EPS Estimate
-1.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.14
Shares Outstanding105,440,210
10 Day Avg. Volume947,663
30 Day Avg. Volume1,271,341
Financial Highlights & Ratios
PEG Ratio-0.28
Price to Book (P/B)4.41
Price to Sales (P/S)568.91
P/FCF Ratio-11.41
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue203.77
Enterprise Value/Gross Profit206.05
Enterprise Value/Ebitda-6.80
Forecast
1Y Price Target
$88.14Price Target Upside114.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.8
Revenue Forecast (FY)$68.57M
Bulls Say, Bears Say
Bulls Say
Early Commercial TractionReporting $10.3M net product revenue and 232 new enrollment forms signals initial product‑market fit and a nascent recurring revenue stream. Durable early sales provide commercial learnings, justify continued investment in sales infrastructure, and reduce the pure binary risk of a pre‑commercial biotech.
Payer Coverage & Reimbursement ProgressAchieving ~70% reimbursement and >60% coverage is structurally important for specialty drugs: it lowers patient access friction, improves predictability of cash flows, and increases the addressable treated population over quarters, supporting more sustainable revenue growth if coverage continues to expand.
Strong Balance Sheet / RunwayA ~$1.3B cash position giving runway into 2030 provides multi‑year funding for commercialization, pivotal trials, and regulatory activities without immediate financing. This financial flexibility supports strategic optionality, reduces short‑term dilution risk, and allows sustained investment in growth initiatives.
Bears Say
High Cash Burn / Negative FCFSustained negative operating cash flow and FCF at ~-$400M TTM means the business must rely on external capital if revenue acceleration slows. High burn constrains the firm's ability to sustain long lead commercial investments indefinitely and elevates dilution or financing risk absent material margin improvement.
Elevated 2026 Expense BaseGuided 2026 expense levels imply a large fixed cost structure relative to current revenue, driven by rising R&D and SG&A. This depresses operating leverage, prolongs the path to breakeven, and increases the sensitivity of financial outcomes to execution in commercialization and reimbursement.
Limited Commercial Conversion TransparencyNot disclosing form‑to‑paid and split‑by‑cohort metrics reduces visibility into true uptake and repeatability of sales. For a nascent launch, absent conversion benchmarks it is difficult to project sustainable revenue ramps, increasing execution risk for investors and partners assessing long‑term commercial potential.
Crinetics Pharmaceuticals News
CRNX FAQ
What was Crinetics Pharma’s price range in the past 12 months?
Crinetics Pharma lowest stock price was $25.83 and its highest was $57.99 in the past 12 months.
What is Crinetics Pharma’s market cap?
Crinetics Pharma’s market cap is $3.44B.
When is Crinetics Pharma’s upcoming earnings report date?
Crinetics Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 68 days.
How were Crinetics Pharma’s earnings last quarter?
Crinetics Pharma released its earnings results on May 07, 2026. The company reported -$1.23 earnings per share for the quarter, missing the consensus estimate of -$1.221 by -$0.009.
Is Crinetics Pharma overvalued?
According to Wall Street analysts Crinetics Pharma’s price is currently Undervalued.
Does Crinetics Pharma pay dividends?
Crinetics Pharma does not currently pay dividends.
What is Crinetics Pharma’s EPS estimate?
Crinetics Pharma’s EPS estimate is -1.22.
How many shares outstanding does Crinetics Pharma have?
Crinetics Pharma has 105,440,210 shares outstanding.
What happened to Crinetics Pharma’s price movement after its last earnings report?
Crinetics Pharma reported an EPS of -$1.23 in its last earnings report, missing expectations of -$1.221. Following the earnings report the stock price went down -13.819%.
Which hedge fund is a major shareholder of Crinetics Pharma?
Currently, no hedge funds are holding shares in CRNX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Crinetics Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$88.14 (114.98% Upside)
$88.14 (114.98% Upside)
Blogger Sentiment
Bullish
CRNX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 2.2M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 4.0%
Last 30 Days ▲ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.28%
12-Months-Change
Fundamentals
Return on Equity
-43.96%
Trailing 12-Months
Asset Growth
2.94%
Trailing 12-Months
Company Description
Crinetics Pharma
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
CRNX Company Deck
CRNX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong early commercial launch for Palsonify with meaningful patient additions, encouraging reimbursement progress (≈70% reimbursed, >60% coverage), expanding prescriber footprint and robust pipeline advancement, all supported by a strong balance sheet. Offsetting these positives are elevated and rising R&D and operating expenses, limited disclosure of certain commercial conversion metrics, a remaining reimbursement gap (~30% of patients), appointment‑driven adoption constraints, and no firm timelines provided for several key pivotal readouts or international revenue. On balance, the positives around launch momentum, payer traction, prescriber growth and cash runway outweigh the operational and disclosure limitations.View all CRNX earnings summariesCRNX Stock 12 Month Forecast
Average Price Target
$88.14
▲(114.98% Upside)
Technical Analysis
Ownership Overview
1.92% Insiders
38.41% Mutual Funds
42.87% Other Institutional Investors
1.54% Public Companies and
Individual Investors